Icomb (Amlodipine, Ramipril)

Icomb is an antihypertensive medication that lowers elevated blood pressure through combined calcium‑channel blockade and angiotensin‑converting‑enzyme inhibition.

• Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure.
• Secondary hypertension: assists in blood‑pressure control when hypertension is caused by another underlying condition.
• Cardiovascular risk reduction: contributes to lower risk of stroke and myocardial infarction in hypertensive individuals.

• Amlodipine blocks L‑type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral resistance. Ramipril inhibits angiotensin‑converting enzyme, decreasing formation of angiotensin II and aldosterone, which leads to vasodilation, reduced sodium retention, and lower blood pressure. The combined actions produce additive antihypertensive effects.

Icomb may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness or light‑headedness: especially after the first dose.
• Flushing: transient warmth and redness of the skin.
• Cough: dry, persistent cough associated with ACE inhibition.
• Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Hyperkalemia: elevated blood potassium levels, particularly with concomitant potassium‑sparing agents.
• Renal impairment: worsening kidney function, especially in patients with pre‑existing disease.

Before initiating Icomb, clinicians should evaluate patient‑specific factors and monitor therapy.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR before and during treatment.
• Electrolyte balance: monitor potassium levels, especially if combined with potassium‑sparing diuretics.
• Hypersensitivity: discontinue if signs of angioedema or severe rash appear.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Icomb can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: combined use may cause renal dysfunction and hyperkalemia.
• Potassium‑sparing diuretics or supplements: risk of dangerous hyperkalemia.
• NSAIDs (e.g., ibuprofen, naproxen): may blunt antihypertensive effect and impair renal function.
• Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may raise amlodipine concentrations.
• Other antihypertensives (beta‑blockers, diuretics): additive blood‑pressure lowering effect.
• Antidiabetic agents: enhanced glucose‑lowering effect, requiring dose adjustment.
• Rifampicin: may reduce ramipril levels, diminishing efficacy.